Belkin Achieves Carbon Neutrality in Scope 1 and Scope 2 Emissions
21.4.2025 09:00:00 CEST | Business Wire | Press release
The company’s 2024 Impact Report showcases bold sustainability progress and innovation
Belkin, a leading consumer electronics brand for 40 years, today published its 2024 Impact Report, announcing its milestone achievement of carbon neutrality in scope 1 and scope 2 emissions, and underscoring its commitment to sustainability and corporate responsibility. With bold progress in carbon reduction and sustainable product design, Belkin remains steadfast in its commitment to finding more responsible ways to build products that enhance lives while preserving the planet for future generations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421326773/en/
Belkin achieves carbon neutrality in scope 1 and scope 2 emissions
“Belkin recently surpassed a monumental milestone: over 1 billion products sold globally. As we reflect on this achievement, we recognize that with scale comes a profound responsibility – to our customers, to the planet, and to future generations,” said Steven Malony, CEO of Belkin. “As we reflect on our 2024 Impact Report, we recognize the progress we’ve made and the work still ahead. We are actively transitioning to post-consumer recycled (PCR) materials across our product lines, using 100% plastic-free packaging, and investing in long-term sustainability strategies to achieve our larger goals of carbon neutrality across our entire business by 2030. Our mission goes beyond creating accessories that empower people to get more life out of every single day – it’s about driving positive change for the planet and its people.”
In the last 12 months, on its journey to carbon neutrality in all scopes by 2030 and in line with its commitment to the UN Sustainable Development Goals, Belkin has achieved:
Climate action (UN Goal 13)
- Carbon neutrality in direct and purchased emissions (Scopes 1 and 2 emissions)
- 1,890 metric tons of CO2e reduced on product level (Scope 3 emissions)
Responsible consumption and production (UN Goal 12)
- 89% reduction in single use plastic packaging (surpassing our 25% reduction goal by 2025)
- 210 metric tons of virgin plastics replaced from 8.8M PCR products sold
- 2,183 metric tons cumulative plastic savings since 2019 (this is the equivalent of 114M water bottles saved)
-
Funding the responsible recycling of:
- 28,445 metric tons of electrical and electronic devices
- 11,463 metric tons of packaging
- 1,358 metric tons of batteries
Made with recycled materials
Two years since introducing its transition to using 72-75% post-consumer recycled (PCR) materials in its products, Belkin has transitioned over 359 products and has replaced 432 metric tons of virgin plastics with PCR materials. This year, several of Belkin’s most popular chargers and cables will receive updated product housing materials that consist of 85-90% PCR and will be certified by the Global Recycling Standard and sold in plastic-free packaging. This initiative is estimated to reduce CO2-eq emissions for these product housing materials by up to 85%.
Award-winning initiatives
Belkin is proud to announce an important achievement in its sustainability journey: receiving a Silver Medal rating from EcoVadis, the globally recognized leader in sustainability ratings. This recognition reflects the company’s ongoing dedication to responsible business practices and positions Belkin among the top-performing companies in the consumer electronics sector evaluated by EcoVadis. Belkin’s overall score ranks in the top 15% globally (91st Percentile) among companies in our industry assessed by EcoVadis.
Shaping a more responsible future
Looking ahead, Belkin remains dedicated to achieving carbon neutrality in all scopes by 2030 and continuously refining its strategy to build products more responsibly. The company is actively investing in circular design principles and exploring innovative ways to further reduce environmental impact without compromising performance or quality.
For more information on Belkin’s sustainability initiatives, visit www.belkin.com/company/sustainability/.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421326773/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom